Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | OGG1 | O15527 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | STAT1 | P42224 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11489877 | 1.00 | CES2 (0.50) | CES2CES1RAB9ALMNARECQL | |
| SCHEMBL4862884 | 1.00 | CES2 (0.50) | CES2CES1RAB9ALMNARECQL | |
| SCHEMBL28863719 | 0.83 | KMT2A (0.36) | RAB9ALMNARECQLMAPTALDH1A1 | |
| SCHEMBL9056522 | 0.80 | ALDH5A1 (0.56) | CES2RAB9ALMNAMAPTALDH1A1 | |
| SCHEMBL4452292 | 0.80 | ALDH5A1 (0.56) | CES2RAB9ALMNAMAPTALDH1A1 | |
| SCHEMBL1193448 | 0.78 | MEN1 (0.53) | CES2CES1RAB9AMAPTCYP1B1 | |
| SCHEMBL14842658 | 0.78 | TPMT (0.48) | LMNAALDH1A1CA1CA2GSK3B | |
| SCHEMBL12997454 | 0.78 | MEN1 (0.53) | CES2CES1RAB9AMAPTCYP1B1 | |
| SCHEMBL14842660 | 0.78 | TPMT (0.48) | LMNAALDH1A1CA1CA2GSK3B | |
| SCHEMBL11436643 | 0.78 | ALDH1A1 (0.61) | CES2CES1RAB9ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470713-B2 | Imidazole based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1175410-B1 | PESTICIDAL TRIAZINE DERIVATIVES | NOVARTIS AG (CH) | 2005-12-07 | — | — | EP | disclosed |
| US-20050187218-A1 | Imidazole based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-25 | — | — | US | disclosed |
| US-6723720-B2 | PHENYL-SUBSTITUTED 1,2,4-TRIAZINES, ESPECIALLY FOR CONTROLLING FLEAS | NOVARTIS ANIMAL HEALTH US, INC. | 2004-04-20 | — | — | US | disclosed |
| US-20030036544-A1 | Pesticidal triazine-derivatives | NOVARTIS ANIMAL HEALTH US, INC. | 2003-02-20 | — | — | US | disclosed |
| EP-1175410-A1 | PESTICIDAL TRIAZINE DERIVATIVES | Syngenta Participations AG (CH) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066568-A1 | PESTICIDAL TRIAZINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2000-11-09 | — | — | WO | disclosed |
| US-4293552-A | Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas | ELI LILLY AND COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
| US-4229579-A | OPTICAL BRIGHTENERS | BAYER AKTIENGESELLSCHAFT (DE) | 1980-10-21 | — | — | US | disclosed |
| US-4160834-A | INSECTICIDES | ELI LILLY AND COMPANY (US) | 1979-07-10 | — | — | US | disclosed |
| US-4144243-A | OPTICAL BRIGHTENERS FOR TEXTILES AND LACQUEARS | BAYER AKTIENGESELLSCHAFT (DE) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187218-A1 | Imidazole based kinase inhibitors | MAP3K19, MAP3K1, ABL1 | CES2 4498/4885CES1 3373/4885RAB9A 1837/4885 |
| US-20030036544-A1 | Pesticidal triazine-derivatives | DDT, CYCS, TUBA3C | CES2 201/4885CES1 194/4885RAB9A 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.